Loading…

Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study

This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes. We reviewed the baseline demographics, c...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in surgery 2023-03, Vol.10, p.1121357-1121357
Main Authors: Bai, Xuesong, Chen, Guo, Shang, Shihai, Li, Senlin, Liu, Huanrui, Feng, Zhenwei, Gou, Xin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3
cites cdi_FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3
container_end_page 1121357
container_issue
container_start_page 1121357
container_title Frontiers in surgery
container_volume 10
creator Bai, Xuesong
Chen, Guo
Shang, Shihai
Li, Senlin
Liu, Huanrui
Feng, Zhenwei
Gou, Xin
description This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes. We reviewed the baseline demographics, clinicopathologic features, perioperative complications, and follow-up data of 44 patients who underwent Cx for pT4 BCa at our institution between 2013 and 2021. The Kaplan-Meier curve and the log-rank test were used to analyze progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analyses were performed using the Cox regression model. The median age of the patients was 68 years [95% confidence interval (CI) 49-81]. Overall, 21 patients (47.7%) were estimated to have a high age-adjusted Charlson comorbidity index (ACCI) score (>4), and nine patients (20.5%) had pT4b substage BCa. None of the patients died of complications within 30-90 days after surgery. Severe complications occurred in 16% (  = 7) of patients within 30-90 days. During a median follow-up of 51 months, disease progression was detected in 25 patients (56.8%), and 29 patients (65.9%) died of any cause. The median PFS and OS were 15.0 and 21.0 months, respectively. The Kaplan-Meier analysis indicated that patients with high ACCI scores or pT4b BCa had worse PFS (  = 0.003 and  = 0.002, respectively) and OS (  = 0.016 and  = 0.034, respectively) than those with low ACCI scores or pT4a BCa. On multivariate analysis, pT4b substage [hazard ratio (HR), 4.166; 95% CI, 1.549-11.206;  = 0.005] and ACCI score >4 (HR, 2.329; 95% CI, 1.105-4.908;  = 0.026) remained independent risk factors for PFS and OS, respectively. Our study revealed that the pT4b substage is associated with a poor prognosis and that the ACCI score is a relevant and practical method to evaluate survival outcomes in patients with pT4 BCa after Cx.
doi_str_mv 10.3389/fsurg.2023.1121357
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3329f76daca345b897b0b5620d35ebd8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3329f76daca345b897b0b5620d35ebd8</doaj_id><sourcerecordid>2799175195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3</originalsourceid><addsrcrecordid>eNpVkstu1DAUhiMEolXpC7BAWbLJ1Jf4xgZVFdBKlVhQJHaWb0ldOXGwnUHzBLw2ns5Qtatj-_znOz723zTvIdhgzMXFkNc0bhBAeAMhgpiwV80pQoJ2nJFfr5-tT5rznB8AABD3kKL-bXOCGcCEMHja_P2xpq3fqtAuyVlvio9zq6Y4j-2iyn0McfSmvetbHZS1LrVGzaaGmvRuLrkdYgjxj696syuxMtbK2Lq6y8WZEqfdp_ayTa6kmBd3yOUqD64zFVBRuax29655M6iQ3fkxnjU_v365u7rubr9_u7m6vO1MT0XpDHaA9oBQpDimBgkCFScCIgABt5hr4RyFZNB1cNuznlpqle45U8ogajU-a24OXBvVg1ySn1Tayai8fDyIaZQqFW-CkxgjMbBabxTuieaCaaBrZ2Axcdryyvp8YC2rnpzdj5NUeAF9mZn9vRzjVkIAGMGAVsLHIyHF36vLRU4-GxeCml1cs0RMCMgIFKRK0UFq6kPm5IanPhDIvSPkoyPk3hHy6Iha9OH5DZ9K_v8__gdhTbcM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2799175195</pqid></control><display><type>article</type><title>Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study</title><source>Open Access: PubMed Central</source><creator>Bai, Xuesong ; Chen, Guo ; Shang, Shihai ; Li, Senlin ; Liu, Huanrui ; Feng, Zhenwei ; Gou, Xin</creator><creatorcontrib>Bai, Xuesong ; Chen, Guo ; Shang, Shihai ; Li, Senlin ; Liu, Huanrui ; Feng, Zhenwei ; Gou, Xin</creatorcontrib><description>This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes. We reviewed the baseline demographics, clinicopathologic features, perioperative complications, and follow-up data of 44 patients who underwent Cx for pT4 BCa at our institution between 2013 and 2021. The Kaplan-Meier curve and the log-rank test were used to analyze progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analyses were performed using the Cox regression model. The median age of the patients was 68 years [95% confidence interval (CI) 49-81]. Overall, 21 patients (47.7%) were estimated to have a high age-adjusted Charlson comorbidity index (ACCI) score (&gt;4), and nine patients (20.5%) had pT4b substage BCa. None of the patients died of complications within 30-90 days after surgery. Severe complications occurred in 16% (  = 7) of patients within 30-90 days. During a median follow-up of 51 months, disease progression was detected in 25 patients (56.8%), and 29 patients (65.9%) died of any cause. The median PFS and OS were 15.0 and 21.0 months, respectively. The Kaplan-Meier analysis indicated that patients with high ACCI scores or pT4b BCa had worse PFS (  = 0.003 and  = 0.002, respectively) and OS (  = 0.016 and  = 0.034, respectively) than those with low ACCI scores or pT4a BCa. On multivariate analysis, pT4b substage [hazard ratio (HR), 4.166; 95% CI, 1.549-11.206;  = 0.005] and ACCI score &gt;4 (HR, 2.329; 95% CI, 1.105-4.908;  = 0.026) remained independent risk factors for PFS and OS, respectively. Our study revealed that the pT4b substage is associated with a poor prognosis and that the ACCI score is a relevant and practical method to evaluate survival outcomes in patients with pT4 BCa after Cx.</description><identifier>ISSN: 2296-875X</identifier><identifier>EISSN: 2296-875X</identifier><identifier>DOI: 10.3389/fsurg.2023.1121357</identifier><identifier>PMID: 37035571</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>age-adjusted charlson comorbidity index ; bladder cancer ; cystectomy ; prognosis ; pT4 ; Surgery</subject><ispartof>Frontiers in surgery, 2023-03, Vol.10, p.1121357-1121357</ispartof><rights>2023 Bai, Chen, Shang, Li, Liu, Feng and Gou.</rights><rights>2023 Bai, Chen, Shang, Li, Liu, Feng and Gou. 2023 Bai, Chen, Shang, Li, Liu, Feng and Gou</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3</citedby><cites>FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075306/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075306/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37035571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bai, Xuesong</creatorcontrib><creatorcontrib>Chen, Guo</creatorcontrib><creatorcontrib>Shang, Shihai</creatorcontrib><creatorcontrib>Li, Senlin</creatorcontrib><creatorcontrib>Liu, Huanrui</creatorcontrib><creatorcontrib>Feng, Zhenwei</creatorcontrib><creatorcontrib>Gou, Xin</creatorcontrib><title>Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study</title><title>Frontiers in surgery</title><addtitle>Front Surg</addtitle><description>This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes. We reviewed the baseline demographics, clinicopathologic features, perioperative complications, and follow-up data of 44 patients who underwent Cx for pT4 BCa at our institution between 2013 and 2021. The Kaplan-Meier curve and the log-rank test were used to analyze progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analyses were performed using the Cox regression model. The median age of the patients was 68 years [95% confidence interval (CI) 49-81]. Overall, 21 patients (47.7%) were estimated to have a high age-adjusted Charlson comorbidity index (ACCI) score (&gt;4), and nine patients (20.5%) had pT4b substage BCa. None of the patients died of complications within 30-90 days after surgery. Severe complications occurred in 16% (  = 7) of patients within 30-90 days. During a median follow-up of 51 months, disease progression was detected in 25 patients (56.8%), and 29 patients (65.9%) died of any cause. The median PFS and OS were 15.0 and 21.0 months, respectively. The Kaplan-Meier analysis indicated that patients with high ACCI scores or pT4b BCa had worse PFS (  = 0.003 and  = 0.002, respectively) and OS (  = 0.016 and  = 0.034, respectively) than those with low ACCI scores or pT4a BCa. On multivariate analysis, pT4b substage [hazard ratio (HR), 4.166; 95% CI, 1.549-11.206;  = 0.005] and ACCI score &gt;4 (HR, 2.329; 95% CI, 1.105-4.908;  = 0.026) remained independent risk factors for PFS and OS, respectively. Our study revealed that the pT4b substage is associated with a poor prognosis and that the ACCI score is a relevant and practical method to evaluate survival outcomes in patients with pT4 BCa after Cx.</description><subject>age-adjusted charlson comorbidity index</subject><subject>bladder cancer</subject><subject>cystectomy</subject><subject>prognosis</subject><subject>pT4</subject><subject>Surgery</subject><issn>2296-875X</issn><issn>2296-875X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkstu1DAUhiMEolXpC7BAWbLJ1Jf4xgZVFdBKlVhQJHaWb0ldOXGwnUHzBLw2ns5Qtatj-_znOz723zTvIdhgzMXFkNc0bhBAeAMhgpiwV80pQoJ2nJFfr5-tT5rznB8AABD3kKL-bXOCGcCEMHja_P2xpq3fqtAuyVlvio9zq6Y4j-2iyn0McfSmvetbHZS1LrVGzaaGmvRuLrkdYgjxj696syuxMtbK2Lq6y8WZEqfdp_ayTa6kmBd3yOUqD64zFVBRuax29655M6iQ3fkxnjU_v365u7rubr9_u7m6vO1MT0XpDHaA9oBQpDimBgkCFScCIgABt5hr4RyFZNB1cNuznlpqle45U8ogajU-a24OXBvVg1ySn1Tayai8fDyIaZQqFW-CkxgjMbBabxTuieaCaaBrZ2Axcdryyvp8YC2rnpzdj5NUeAF9mZn9vRzjVkIAGMGAVsLHIyHF36vLRU4-GxeCml1cs0RMCMgIFKRK0UFq6kPm5IanPhDIvSPkoyPk3hHy6Iha9OH5DZ9K_v8__gdhTbcM</recordid><startdate>20230322</startdate><enddate>20230322</enddate><creator>Bai, Xuesong</creator><creator>Chen, Guo</creator><creator>Shang, Shihai</creator><creator>Li, Senlin</creator><creator>Liu, Huanrui</creator><creator>Feng, Zhenwei</creator><creator>Gou, Xin</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230322</creationdate><title>Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study</title><author>Bai, Xuesong ; Chen, Guo ; Shang, Shihai ; Li, Senlin ; Liu, Huanrui ; Feng, Zhenwei ; Gou, Xin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>age-adjusted charlson comorbidity index</topic><topic>bladder cancer</topic><topic>cystectomy</topic><topic>prognosis</topic><topic>pT4</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bai, Xuesong</creatorcontrib><creatorcontrib>Chen, Guo</creatorcontrib><creatorcontrib>Shang, Shihai</creatorcontrib><creatorcontrib>Li, Senlin</creatorcontrib><creatorcontrib>Liu, Huanrui</creatorcontrib><creatorcontrib>Feng, Zhenwei</creatorcontrib><creatorcontrib>Gou, Xin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Xuesong</au><au>Chen, Guo</au><au>Shang, Shihai</au><au>Li, Senlin</au><au>Liu, Huanrui</au><au>Feng, Zhenwei</au><au>Gou, Xin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study</atitle><jtitle>Frontiers in surgery</jtitle><addtitle>Front Surg</addtitle><date>2023-03-22</date><risdate>2023</risdate><volume>10</volume><spage>1121357</spage><epage>1121357</epage><pages>1121357-1121357</pages><issn>2296-875X</issn><eissn>2296-875X</eissn><abstract>This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes. We reviewed the baseline demographics, clinicopathologic features, perioperative complications, and follow-up data of 44 patients who underwent Cx for pT4 BCa at our institution between 2013 and 2021. The Kaplan-Meier curve and the log-rank test were used to analyze progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analyses were performed using the Cox regression model. The median age of the patients was 68 years [95% confidence interval (CI) 49-81]. Overall, 21 patients (47.7%) were estimated to have a high age-adjusted Charlson comorbidity index (ACCI) score (&gt;4), and nine patients (20.5%) had pT4b substage BCa. None of the patients died of complications within 30-90 days after surgery. Severe complications occurred in 16% (  = 7) of patients within 30-90 days. During a median follow-up of 51 months, disease progression was detected in 25 patients (56.8%), and 29 patients (65.9%) died of any cause. The median PFS and OS were 15.0 and 21.0 months, respectively. The Kaplan-Meier analysis indicated that patients with high ACCI scores or pT4b BCa had worse PFS (  = 0.003 and  = 0.002, respectively) and OS (  = 0.016 and  = 0.034, respectively) than those with low ACCI scores or pT4a BCa. On multivariate analysis, pT4b substage [hazard ratio (HR), 4.166; 95% CI, 1.549-11.206;  = 0.005] and ACCI score &gt;4 (HR, 2.329; 95% CI, 1.105-4.908;  = 0.026) remained independent risk factors for PFS and OS, respectively. Our study revealed that the pT4b substage is associated with a poor prognosis and that the ACCI score is a relevant and practical method to evaluate survival outcomes in patients with pT4 BCa after Cx.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>37035571</pmid><doi>10.3389/fsurg.2023.1121357</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2296-875X
ispartof Frontiers in surgery, 2023-03, Vol.10, p.1121357-1121357
issn 2296-875X
2296-875X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_3329f76daca345b897b0b5620d35ebd8
source Open Access: PubMed Central
subjects age-adjusted charlson comorbidity index
bladder cancer
cystectomy
prognosis
pT4
Surgery
title Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A07%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20prediction%20among%20pathologic%20T4%20bladder%20cancer%20patients%20following%20cytoreductive%20cystectomy:%20A%20retrospective%20single-center%20study&rft.jtitle=Frontiers%20in%20surgery&rft.au=Bai,%20Xuesong&rft.date=2023-03-22&rft.volume=10&rft.spage=1121357&rft.epage=1121357&rft.pages=1121357-1121357&rft.issn=2296-875X&rft.eissn=2296-875X&rft_id=info:doi/10.3389/fsurg.2023.1121357&rft_dat=%3Cproquest_doaj_%3E2799175195%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2799175195&rft_id=info:pmid/37035571&rfr_iscdi=true